Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, according to experts presenting at the 37th European Congress of Pathology in Vienna this September. During a session on state-of-the-art in gastrointestinal biomarkers, speakers outlined how targeted therapies and immunotherapies are transforming treatment options – but emphasized that pathologists must remain at the center of this evolution.
English (US) ·